Mediclinic International (LON:MDC)‘s stock had its “neutral” rating reiterated by JPMorgan Chase & Co. in a report released on Tuesday, December 12th. They presently have a GBX 695 ($9.29) target price on the stock. JPMorgan Chase & Co.’s target price would suggest a potential upside of 11.02% from the stock’s previous close.
Several other equities analysts also recently commented on MDC. Jefferies Group lowered their target price on shares of Mediclinic International from GBX 650 ($8.69) to GBX 550 ($7.35) and set an “underperform” rating on the stock in a research report on Monday, September 25th. Citigroup lowered their target price on shares of Mediclinic International from GBX 790 ($10.56) to GBX 720 ($9.63) and set a “neutral” rating on the stock in a research report on Wednesday, October 18th. Macquarie lowered their target price on shares of Mediclinic International from GBX 760 ($10.16) to GBX 660 ($8.82) and set a “neutral” rating on the stock in a research report on Friday, October 20th. Finally, Credit Suisse Group increased their target price on shares of Mediclinic International from GBX 265 ($3.54) to GBX 305 ($4.08) and gave the stock a “neutral” rating in a research report on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of GBX 704.56 ($9.42).
Shares of Mediclinic International (MDC) traded down GBX 6.40 ($0.09) during trading hours on Tuesday, hitting GBX 626 ($8.37). The company had a trading volume of 2,488,696 shares, compared to its average volume of 1,990,000. Mediclinic International has a twelve month low of GBX 495.40 ($6.62) and a twelve month high of GBX 890.18 ($11.90). The stock has a market capitalization of $4,590.00 and a price-to-earnings ratio of 6,955.56.
COPYRIGHT VIOLATION WARNING: “Mediclinic International (LON:MDC) Stock Rating Reaffirmed by JPMorgan Chase & Co.” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/01/05/j-p-morgan-chase-co-reiterates-neutral-rating-for-mediclinic-international-mdc.html.
Mediclinic International Company Profile
Mediclinic International plc is an international private healthcare provider. The Company’s segments include Mediclinic Southern Africa, Mediclinic Switzerland, Mediclinic Middle East, United Kingdom and Corporate. It focuses on providing acute care and multidisciplinary healthcare services. It has interest in Spire Healthcare, a United Kingdom-based private healthcare company.
Receive News & Ratings for Mediclinic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediclinic International and related companies with MarketBeat.com's FREE daily email newsletter.